PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Immunol. Author manuscript; available in PMC 2009 November 30.
Published in final edited form as:
PMCID: PMC2785500
NIHMSID: NIHMS150977

TLR-9 Activation Coupled To IL-10 Deficiency Induces Adverse Pregnancy Outcomes

Abstract

Pregnancy outcome is severely compromised by intrauterine infections and inflammation. Although the pregnant uterine microenvironment is replete with innate immune cells and Toll-like receptor (TLR) expression, the mechanisms that facilitate adverse effects of their activation are largely unknown. Here we mimic the activation of TLR-9 with its pathogenic ligand hypomethylated CpG, and demonstrate that IL-10 proficiency protects against CpG-induced pregnancy complications. We show that fetal resorption and preterm birth are rapidly induced in IL-10−/− mice by low doses of CpG (~25 µg/mouse) when injected i.p. on gestational day (gd)6 or gd14, respectively. In contrast, wild type (WT) mice failed to experience such effects at comparable doses, but pups born at term displayed craniofacial/limb defects in response to higher doses (~400 µg/mouse). Pregnancy complications in IL-10−/− mice were associated with unexpected and robust TLR-9-triggered activation and amplification of uterine neutrophil and macrophage subpopulations followed by their migration to the placental zone. Further, a dramatic increase in serum levels of mouse KC (mKC) and TNF-α production by uterine F4/80+ cells, but not uterine NK or GR1+/CD11b+ cells, was observed. Depletion of F4/80+ macrophages or neutralization of TNF-α rescued pregnancy to term. Our results have important implications for IL-10-mediated “uterine tolerance” against CpG-driven innate immune activation.

Keywords: Reproductive Immunology, Macrophage, Neutrophils, Cytokines/Chemokines, Inflammation

Pregnancy outcome is severely compromised by intrauterine infections and inflammation. Although the pregnant uterine microenvironment is replete with innate immune cells and Toll-like receptor (TLR) expression, the mechanisms that facilitate adverse effects of their activation are largely unknown. Here we mimic the activation of TLR-9 with its pathogenic ligand hypomethylated CpG, and demonstrate that IL-10 proficiency protects against CpG-induced pregnancy complications. We show that fetal resorption and preterm birth are rapidly induced in IL-10−/− mice by low doses of CpG (~25 µg/mouse) when injected i.p. on gestational day (gd)6 or gd14, respectively. In contrast, wild type (WT) mice failed to experience such effects at comparable doses, but pups born at term displayed craniofacial/limb defects in response to higher doses (~400 µg/mouse). Pregnancy complications in IL-10−/− mice were associated with unexpected and robust TLR-9-triggered activation and amplification of uterine neutrophil and macrophage subpopulations followed by their migration to the placental zone. Further, a dramatic increase in serum levels of mouse KC (mKC) and TNF-α production by uterine F4/80+ cells, but not uterine NK or GR1+/CD11b+ cells, was observed. Depletion of F4/80+ macrophages or neutralization of TNF-α rescued pregnancy to term. Our results have important implications for IL-10-mediated “uterine tolerance” against CpG-driven innate immune activation.

Introduction

A common link for a significant proportion of early and late pregnancy maladies lies in intrauterine infections and inflammation (1, 2). In this regard, the role of the innate immune system at the maternal-fetal interface in response to normal pregnancy intrauterine milieu or inflammatory stimuli has attracted an abundance of recent interest. Although a vigorous uterine immune system juxtaposes the fetal tissue predominated by innate sentinels, NK cells and macrophages, it does not pose any intolerance to normal fetal development and survival of invading trophoblasts (35). We and others have proposed that uterine NK cells (uNK) produce angiogenic and pregnancy compatible factors, and are involved in local endovascular processes and regulation of trophoblast invasion (3, 68). On the other hand, in a mouse model, we have demonstrated that uNK cells become antagonistic to pregnancy in response to bacterial products (9, 10). Thus, the underlying mechanisms of diverse pathogen-mediated inflammatory events that may trigger cytotoxic activation of maternal immune cells and trophoblasts require further exploration.

A group of innate immune sentinel receptors known as Toll-like receptors (TLRs) are present not only on uterine leukocytes, but also on trophoblast cells thus implying an active cross-talk between the placenta and local immunity (1113). TLRs have evolved to recognize specific pathogen-associated molecular patterns (PAMPS) enabling them to serve as the first line of defense in the innate immune system (14, 15). Although TLRs are ancient receptors without memory requirements for cells that express them, they harbor the ability to transduce both negative and positive signals depending on interactions with their immediate microenvironment (16). Moreover, pathogenic load and gene-environment interactions are likely to be over-riding factors in the outcome of inflammation- induced positive versus negative cascades. Our recent studies provide support to this hypothesis in that very low doses of lipopolysaccharide (LPS) cause adverse pregnancy outcomes in IL-10−/− mice compared to their wild type counterparts (9, 10).

Systemic or intrauterine bacterial and viral infectious agents, and their breakdown products, are likely to lead to the excessive presence of pathogenic hypomethylated CpG DNA motifs which are recognized by TLR-9 (1718). Few studies have focused on the role of TLR-9-mediated immune activation during pregnancy. Using C57BL/6 mice, it has been shown that high doses of CpG cause deformities in pups born to treated dams (19). On the other hand, CpG has been used as an adjuvant to reduce negative fetal outcomes induced by Lysteria Monocytogenes in BALBc pregnant dams (20). In other settings, it has been shown that direct injection of CpG DNA in neuroblastomas induces complete tumor rejection in mice and elicits long-term Th-1 driven immunity (21). In addition, anti-tumor effects of CpG have been demonstrated in different intracranial models of syngeneic glioma (22, 23). These observations imply that CpG motifs are capable of triggering strong and polarized immune responses which may be beneficial or harmful depending on the intrinsic microenvironment.

Given the proposed widespread use of CpG as a treatment and vaccine tool among the general population, including pregnant individuals, it is important to determine whether over-activation of the immune system in response to non-teratogenic doses of CpG can lead to negative pregnancy outcomes (20, 2428). In this study, we examined the role of the CpG-TLR-9 axis in a mouse model of pregnancy with a focus on the protective role of pregnancy compatible cytokines such as IL-10. CpG-induced TLR-9 activation has been associated mainly with stimulation of systemic immunity. Our observations allow us to elucidate a link between CpG-mediated activation of innate immune responses and IL-10 deficiency at the maternal-fetal interface that leads to adverse pregnancy outcomes.

Materials and Methods

Mice

Mice used in this study, C57BL/6 and C57BL/6 IL-10−/−, were obtained from The Jackson Laboratory. All mice were housed in a specific pathogen-free facility supervised by the Central Research Department of Rhode Island Hospital. All protocols were approved by the Lifespan Animal Welfare Committee and conducted according to its guidelines. Mice of 8–10 weeks’ age were mated and each experimental group contained at least 3 mice. The day of vaginal plug appearance was designated gestational day (gd)0.

In vivo treatment of pregnant mice

Wild type (WT) and IL-10−/− mice received i.p. injections of CpG ODN (oligodeoxynucleotide) (ODN 1826, Invivogen) at doses of 15, 25, 100, 300 or 400 µg on gd6 or 14. For IL-10−/− mice, suitable doses were 15 or 25 µg/dam as higher doses caused maternal demise. Cellular depletions were performed with CpG injection on gd6 or gd14. 100 µl anti-asialo GM1 (Wako) or non-immune rabbit serum (Antibodies Inc.) was administered on gd4, 6, and 9 or gd9, 11, and 14 for NK cell depletion. 250 µg anti-GR1 (RB6-8C5, BD Biosciences) or isotype Ab (Rat IgG1, BD Biosciences) was administered at gd5. 250 µg anti-F4/80 (BM8, eBioscience) or isotype Ab (Rat IgG2a, κ, eBioscience) was given on gd5 and 7, or gd13 and 15. Competitive antagonist experiments were performed in IL-10−/− mice and i.p. injections of 100 µg or 50 µg antagonist ODN (ODN 2088, Invivogen) were given with 25 µg CpG ODN on gd6. Control experiments were performed using 50, or 100 µg antagonist ODN alone, or 50 or 100 µg antagonist ODN plus 25 µg CpG ODN on gd6. Monoclonal anti-TNF-α Ab (Gr81-2626, BD Pharmingen) was administered i.p. at 250 µg on gd5 and gd7 with CpG ODN injection on gd6 or on gd13 and gd15 with CpG ODN injection on gd14.

Cellular preparation

Uterine mononuclear and granular cells (UMGC) were obtained via mincing and mechanical dispersion of whole gd 8–9 or gd15 uteroplacental tissue in RPMI 1640 supplemented with 10% FBS, penicillin/streptomycin, and L-glutamine. Single cell suspensions from uterine horns were run through a 100 µm cell-strainer and subjected to density gradient separation using Fico-Lite LM (Atlanta Biologicals). Experiments were performed on the three layers obtained from ficoll gradient separation to determine in which layer granulocytes accumulated. It was found that granulocytes collect directly below the monocyte layer, and both layers were harvested together for all experiments.

Flow cytometry

Antibodies to NK1.1 (NKR-PIC), CD3 (145-2C11), CD45 (30-F11), F4/80 (BM8), GR1(RB6-8C5), CD11b (M1/79), and Ly6G (1A8) were purchased (BD Biosciences). Isolated UMGC were washed in PBS and resuspended in PBS containing 2% FBS (stain buffer). Combinations of antibodies were added for extracellular staining for 30 minutes at 4°C, rinsed with stain buffer and acquired via flow cytometry (FACS Canto, Becton Dickinson). Fluorochrome-conjugated isotype matched antibodies were used as controls. Antibodies to TNF-α (MP6-XT22)and IFN-γ (XMG1.2) were purchased for intracellular staining (BD Biosciences). UMGC were washed with stain buffer and incubated in 96-well plates for 4–6 hours with Brefeldin-A (BD Biosciences), Phorbol-12-myristate-13-acetate (PMA) (Calbiochem), and Ionomycin (Calbiochem). Cells were washed twice with stain buffer and stained extracellularly as described above. For intracellular staining UMGC were washed with Perm Wash (BD Biosciences) and fixed with Cytofix/Cytoperm (BD Biosciences) for 25 min at 4°C, and incubated with antibodies for 30 min at RT. Cells were washed and analyzed via flow cytometry.

Intracellular ROS production was assessed with dihydrorhodamine 123 (DHR; Sigma-Aldrich) by flow cytometry. This non-fluorescent dye becomes fluorescent upon oxidation to rhodamine by ROS produced during the respiratory burst. Directly after UMGC were prepared, DHR (10 µmol/ml) was added simultaneously with antibodies GR1, CD45, CD11b, or with irrelevant isotype antibodies, and the mixture was incubated at 37°C for 15 min. UMGC were washed and immediately processed by flow cytometry.

ELISA

TNF-α IL-12, IFN-γ, mKC, MIP-1α and MIP-2 were measured in serum. Blood samples were collected via cardiac puncture into 1 ml tubes, allowed to clot for 30 min at RT, spun at 8,000 rpm for 20 min at 4°C, and supernatants were collected and frozen for further analysis. TNF-α, IL-12, IFN-γ, mKC, MIP-1α and MIP-2 were assayed using Quantikine ELISA kits (R&D Systems) and experiments were performed according to the manufacturer’s instructions. Separate serum samples were collected from each experimental treatment group (n=9).

Immunohistochemistry

Feto-placental units from varying experimental conditions were removed from uterine horns and placed in 4% buffered formalin or snap frozen in a cassette with OCT. Samples in the latter treatment were paraffin embedded 24 hours post fixation. Staining for mKC (KC Rabbit Polyclonal Antibody, BioVision) was performed on paraffin embedded tissue from gd9 or gd15 treated and control matched samples as previously described (59). F4/80+ (MCA497R rat and mouse antigen, Serotec) cells were detected using paraffin embedded tissue as described previously (60). GR-1 (Purified Rat anti-mouse Ly6-G and Ly6-C, BD Biosciences) staining was performed on frozen gd9 and gd15 tissue cut into 10-µm sections as described previously (45).

Statistical analysis

Statistical significance of pregnancy outcomes was examined using 1-way analysis of variance method. All experiments where flow cytometry plots were analyzed for n=3 or more animals per condition and significance was assessed via t test. Data are expressed as means by ±SD. A P value of ≤.05 was considered to be statistically significant.

Results

CpG ODN treatment induces fetal resorption and preterm birth in IL-10−/− Mice

We studied the effect of CpG oligodeoxynucleotide (ODN) treatment on pregnancy in either a fetal resorption or preterm birth model using C57BL/6 mice. The CpG ODN motif, CpG 1826, employed in these studies has been widely used to trigger B or T Cell-specific immunity (29, 30). In order to assess the ability of CpG ODN to induce fetal resorption, we injected i.p. varying doses of CpG ODN in IL-10−/− or WT mice on gestational day (gd)6. We initially tested a dose range from 5 to 400 µg/dam and found that the 25 µg dose was optimal in IL-10−/− mice to induce complete resorption of uterine horns. At the dose of 100 µg/dam or higher, we observed maternal wasting in IL-10−/− mice. As Fig. 1A demonstrates, fetal resorption was consistently observed in IL-10−/− mice in numerous matings (n=37) at the 25 µg/dam dose. In contrast, no negative pregnancy effects were observed at this dose in WT mice (n=8) as they maintained pregnancy to term (~20 days) and delivered healthy pups.

Figure 1
Dose dependent CpG ODN-mediated induction of fetal resorption and preterm birth in WT or IL-10−/− mice

Next, we aimed to find a dose of CpG ODN that caused a negative pregnancy outcome in WT mice in response to gd6 administration. A range of doses up to 250 µg/dam did not exert any adverse consequences on pregnancy outcome or gestational length. However, at a dose of 400 µg/dam, a significant number of pups (43%) were born at term with cranial and distal limb malformations (Fig. 1C). These results are consistent with previously published data demonstrating similar deformities to pups born to dams treated with 300 µg CpG ODN (19).

We have previously shown that LPS administered to IL-10−/− and WT mice on gd14 induces preterm birth on gd17, albeit at 20 fold higher doses in WT mice (10). For preterm birth outcomes in response to CpG ODN administration, a similar approach was employed. CpG ODN was administered i.p. on gd14 and mice were checked twice daily for preterm birth of newborns. As shown in Fig. 1B, IL-10−/− mice (n=18) consistently delivered stillborn pups at a dose of 15 µg/dam within 24–48 hours of injection. Lower doses of CpG ODN failed to induce preterm delivery. Similar to fetal resorption observations, WT mice (n=4) failed to experience any negative consequences of CpG ODN administration at a comparable or higher dose in the range of 300 µg/dam (n=8), except for deformities at higher doses similar to that shown in Fig. 1C.

Regarding fetal resorption in IL-10−/− mice, we noted that effects were rapid with severe utero-placental pathology at 25 µg CpG ODN (Fig. 1A). In order to characterize the kinetics and general pathology in IL-10−/− mice in response to CpG ODN administration, we visually assessed fetal resorption from gd7 through gd9. Fig. 2A demonstrates fetal resorption at 25 µg CpG ODN as observed in uterine horns harvested as early as gd7 and the placental pathology appeared to increase in severity on gd8 and gd9. In contrast, control ODN-treated mice did not experience fetal resorption.

Figure 2
CpG ODN-induced fetal resorption in IL-10−/− occurs with rapid kinetics and is TLR-9 dependent

CpG ODN-mediated effects on pregnancy outcome are TLR-9 dependent

CpG ODN 1826 is a promiscuous molecule which may signal not just through TLR-9, but also through an extracellular receptor (31, 32). Thus, we assessed whether negative pregnancy outcomes in IL-10−/− mice were due to direct TLR-9 stimulation. To address this issue, we employed CpG ODN 2088 (antagonist ODN), an ODN sequence which binds intracellular TLR-9 with high affinity but does not induce downstream stimulation of the TLR pathway (3335). Antagonist ODN injected on gd6 did not induce any pathology in placental units harvested on gd9 (Fig. 2B). Importantly, mice treated with antagonist ODN when allowed to deliver gave birth to healthy litters at term. Antagonist ODN, when used with pathogenic CpG ODN at a 4:1 or 2:1 ratio, blocked fetal resorption compared to CpG ODN alone as demonstrated by normal placental units (Fig. 2B). If allowed to deliver, antagonist ODN plus CpG ODN treated mice gave birth to healthy pups. These results demonstrate that antagonist ODN was able to successfully blunt the TLR-9 receptor-mediated signaling and displace the binding of CpG ODN at a dose ratio as low as 2:1 as demonstrated by lack of resorption on gd9.

CpG ODN administration in IL-10−/− mice results in amplification and placental migration of uterine macrophages and neutrophils

In normal pregnancy, uNK cells, macrophages, and low numbers of T cells, but not GR1+/CD11b+ cells, are normally detected in the pregnant mouse uterus by gd7 (4, 36, 37). These cells remain localized to the maternal side of uteroplacental tissue within the mesometrial triangle and decidua basalis. However, it is not yet clear whether these uterine immune cells acquire a cytotoxic phenotype and migrate to the placental zone to cause local damage. In this regard, we have recently shown for the first time that uNK cells are indeed activated in response to LPS administration and cause apoptosis in the placental region (10). It is possible that severe and rapid pathology in CpG ODN-treated mice (Fig. 1Fig. 2A) may be programmed by the mechanisms of cellular activation and placental injury.

There is abundant evidence in non-pregnant mice that CpG ODN treatment leads to activation of dendritic cells (38). We prepared single cell suspensions of CD45+ uterine mononuclear and granular cells as described in Materials and Methods and utilized flow cytometry to probe for the presence of CD11c+(dendritic cells), CD11b+/GR1+ (neutrophils), CD11b+/F4/80+ (macrophages), or NK1.1+/CD3 (uNK cells) in IL-10−/− and WT mice treated or untreated with CpG ODN. In the case of fetal resorption, we harvested uterine tissue and spleen on gd8–9, whereas for the preterm birth setting, we harvested uterine tissue and spleen 24 hours post CpG ODN injection on gd15. Surprisingly, we did not see any changes in the dendritic cell populations of IL-10−/− or WT mice treated with 25 µg CpG ODN on gd6 (data not shown).

Interestingly, analysis of gd8–9 uterine mononuclear and granular cells from CpG ODN-treated IL-10−/− mice showed a significant increase in the CD11b+/GR1+ cellular population compared to vehicle treated mice (9.3±2.5 to 28.8±4.4%) (Fig. 3A). Similarly, we observed an increase in the CD11b+/GR1+ cellular population in IL-10−/− mice under preterm birth conditions when analyzed on gd15 (6±1.4 to 23.7±3.5%) (Fig. 3A). A simultaneous increase occurred in CD11b+/F4/80+ populations. When analyzed on gd8–9, this population increased from 11.1±0.9% to 35.0±4.0%, and a similar increase occurred in the preterm birth condition 9.5±3.1% to 25±2.6% (Fig. 3C). At the doses utilized to induce fetal resorption or preterm birth in IL-10−/− mice, we did not observe any significant changes in either of these cellular populations in WT mice (Fig. 3B, D).

Figure 3
CD11b+/GR1+ and CD11b+/F4/80+ uterine cell populations amplify in response to CpG ODN in IL-10−/−, but not WT mice

Analysis of uNK cells revealed a slight increase in NK1.1+/CD3 cells in CD45+ mononuclear and granular cells from gd8–9 and gd15 tissues from IL-10−/− but not wild type mice. However, depletion of uNK cells using anti-asialo GM1 antibody proved ineffective in rescuing fetal resorption or preterm birth in IL-10−/− mice treated with CpG ODN (data not shown). Thus, we focused on the role of macrophages and neutrophils in adverse pregnancy outcomes as these cells were highly amplified in response to CpG ODN treatment.

Mouse KC (mKC) is significantly induced in CpG ODN-treated IL-10−/− mice

We addressed the possibility that a suitable chemokine was induced in response to CpG ODN treatment in IL-10−/− mice that led to the unscheduled recruitment and amplification of granulocyte and monocyte (CD11b+/GR1+, or CD11b+/F4/80+) cellular populations. Initial screening was done for serum levels of MIP-1α, MIP-2 and mKC using chemokine specific ELISAs. No significant changes were observed for MIP-1α or MIP-2 in serum samples from control ODN or CpG ODN-treated mice (data not shown). However, mKC, the mouse homologue of human IL-8 and a known chemo-attractant of macrophages and neutrophils (39, 40), was markedly increased in samples from CpG ODN-treated IL-10−/− but not wild type mice. The mKC levels in sera collected on gd9 from IL-10−/− mice averaged 94.3±42.5 pg/ml in control ODN-treated mice, and increased to an average of 319.1±85.7 pg/ml in CpG ODN-treated mice, demonstrating a significant difference, (Fig. 4A). Under identical conditions, no significant differences were observed in WT mice (Fig. 4A). Sera collected from gd15, IL-10−/− mice showed larger increases in mKC levels from an average of 63.4±7.4 pg/ml in control animals (n=9), to an average of 1242.9±311.2 pg/ml in CpG ODN -treated animals (n=9) with no significant changes in WT mice (Fig. 4B). IL-8 has been shown to be intrinsically produced at physiological levels by human uNK cells and it has been proposed that this chemokine might be involved in recruitment of invading trophoblasts or macrophages for placental growth (6). We hypothesize that increased levels of mKC in response to CpG ODN motifs are responsible for the increased presence of CD11b+/GR1+ and CD11b+/F4/80+ cells in the uterine microenvironment.

Figure 4
CpG ODN treatment leads to elevated production of mKC in IL-10−/− mice

While an increase in serum mKC was observed, we wanted to determine that this protein was also produced locally at the maternal-fetal interface in response to CpG ODN. We performed mKC-specific immunostaining on paraffin-embedded sections of CpG ODN-treated utero-placental tissue from IL-10−/− mice obtained on gd9 or gd15. Although tissue from control ODN-treated mice showed basal mKC staining in the mesometrial (M) and developing placental (P) regions on gd9 or gd15 (Fig. 4C–D), CpG ODN treatment resulted in intense staining throughout the tissue organization collected from gd9 or gd15. Isotype control antibody failed to stain any specific regions of tissue sections (Fig. 4C–D)

CpG ODN-activated GR1+ and F4/80+ uterine cells migrate to the placenta in IL-10−/− mice

As mentioned earlier, uterine immune cells remain localized to the maternal part of uteroplacental tissue (3, 5, 9, 37). In this study, we tested the hypothesis that CpG ODN treatment imparts migration of GR1+ and F4/80+ uterine cells to the placenta leading to adverse pregnancy outcomes. GR1+ populations can be indicative of macrophages or neutrophils, thus we first aimed to specify the contribution of each of these particular cell types at the placental level. From tissues harvested on gd9 and gd15, we isolated mononuclear and granular cells and analyzed the CD45+ population by FACS for macrophage or neutrophil markers F4/80 and Ly6G, respectively. F4/80 positivity was markedly increased in both the fetal resorption (10.5±1.3 to 21.5±1.3%) and preterm birth conditions over control levels (6.5±1.3 to 21.0±3.1%) (Fig. 5A). We next examined whether F4/80+ cells migrated to the placental zone. Utero-placental tissue from gd9 was processed for immunohistochemical analysis of F4/80 positive staining (Materials and Methods). As shown in Fig. 5C, no significant staining was observed with isotype antibody in CpG ODN-treated tissue. However, there was an abundance of F4/80+ cells that were found not only in the mesometrial zone but also in the placental zone at gd9 (Fig. 5C). Control ODN-treated tissue showed low levels of F4/80+ cells localized only to mesometrial zone (data not shown).

Figure 5
Macrophages and neutrophils migrate into the placental zone in response to CpG ODN in IL-10−/− mice

We next aimed to delineate the specific presence of neutrophils in utero-placental tissue. As shown in Fig. 3, GR1+ cells increased significantly in the CD45+ uterine population from CpG ODN-treated IL-10−/− mice. The GR1 receptor is composed of the Ly-6G and Ly-6C sub-receptors (41). While it is commonly accepted in the literature that GR1 positive cells are representative of neutrophils, we assessed these cells using the Ly-6G antibody. As shown in Fig. 5B, Ly-6G+ cells increased significantly from control levels in both gd9 (5.7±1.7 to 53.2±7.1%) and gd15 (7.8±3.0 to 28.3±6.5%) tissues. Immunohistochemical analysis further demonstrated migration of GR1+ cells well into the placental zone in tissue harvested on gd9 from CpG ODN treated IL-10−/− mice (Fig. 5D). Taken together, these data imply that migration of macrophages and neutrophils to the placenta may lead to pathologic outcomes.

TNF-α functions as the regulator of CpG ODN-mediated pregnancy loss

As discussed above, mKC was detected at high levels in serum of CpG ODN-treated IL-10−/− mice, suggesting that it could contribute to pregnancy complications. However, experiments involving mKC neutralization did not result in rescue of pregnancy (data not shown). We hypothesized that a distinct cytotoxic factor(s) was produced by macrophages and/or neutrophils that induced adverse pregnancy outcomes in IL-10−/− mice. CpG ODN is known to induce the expression of a variety of cytotoxic proteins, including IFN-γ, TNF-α, and IL-12 (42). We measured the concentration of IFN-γ, IL-12, and TNF-α in serum samples collected on gd9 from mice treated with 25 µg CpG ODN or control ODN on gd6, as well as in gd15 serum from mice treated with 15 µg CpG ODN or control ODN on gd14. In both the fetal resorption (50.1±15.0 to 168±30.9 pg/ml) (Fig. 6A) and preterm birth conditions (51.0±11.9 to 196.9±36.1 pg/ml) (Fig. 6B), we noted a significant increase in serum TNF-α levels in CpG ODN-treated IL-10−/− mice, but not in CpG ODN-treated WT mice. No significant differences were observed for IFN-γ and IL-12 between treated or untreated IL-10−/− or WT mice (data not shown).

Figure 6
TNF-[alpha] is the essential cytotoxic factor leading to fetal resorption or preterm birth in response to CpG ODN in IL-10−/− mice

Due to the increased levels of this toxic cytokine in serum in response to CpG ODN, we aimed to determine whether TNF-α was being produced within the uterine tissue of CpG ODN-treated IL-10−/− mice. Uterine monocytes and granulocyte populations were isolated and intracellular staining for TNF-α was performed as described in Materials and Methods. Uterine CD45+ cells from CpG ODN-treated tissue showed a marked increase in intracellular TNF-α production as compared to those from control ODN treated tissue from gd9 (8.25±1.7 to 40.5±8.3%) (Fig. 6C). Similar results were obtained from uterine cells isolated from gd15 tissue (6.25±2.0 to 21.5±3.3%) (Fig. 6D).

Since we noted a significant increase in TNF-α both in serum and in uterine CD45+ cells in CpG ODN-treated IL-10−/− mice, we aimed to determine whether this cytokine played a critical role in adverse pregnancy outcomes. We utilized a neutralizing antibody for in vivo inactivation of TNF-α. In the context of early pregnancy loss, we injected anti-TNF-α antibody on gd5 and gd7 in combination with a CpG ODN injection on gd6. First, we noted healthy litters were born at term in mice treated at the aforementioned time points. Correspondingly, mice treated with CpG ODN on gd6 showed intact fetal-placental units on gd10 in response to anti-TNF-α treatment (Fig. 6E). Similarly, mice treated with CpG ODN on gd14 gave birth to healthy litters at term when given injections of anti-TNF-α antibody on gd13 and 15 (Table I).

Table I
Rescue of CpG ODN-induced preterm birth in IL-10−/− mice

GR1+ cellular depletion in IL-10−/− mice does not lead to pregnancy rescue or reduced TNF-α production

We sought to examine the cellular origin of TNF-α and the role that CD11b+/GR1+ populations played in CpG ODN-induced fetal demise in IL-10−/− mice. We first assessed the effects of depletion of GR1+ cells. We used an anti-GR1+ antibody which was administered i.p. in one dose on gd5 with a CpG ODN injection on gd6 followed by euthanization of animals on gd9 in order to determine whether rescue from fetal resorption ensued. As shown in Fig. 7A, anti-GR1+ antibody treatment depleted GR1+ cells in CpG ODN-treated IL-10−/− mice. However, this event was not associated with the depletion of a CD45+/TNF-α+ producing population as assessed simultaneously by intracellular FACS staining (Fig. 7A). In addition, depletion of GR1+ cells did not rescue pregnancy. These observations suggest that the large infiltrates of Ly6G+/GR1+ cells in response to CpG ODN-treatment (Fig. 5B, D) play a secondary role in induction of CpG ODN-mediated fetal resorption or preterm birth.

Figure 7
GR1 depletion does not rescue CpG ODN-mediated negative fetal outcomes in IL- 10−/− mice, but GR1+ cells actively produce ROS

Evidence of respiratory burst in uterine GR1+/CD11b+ cells from CpG ODN-treated IL-10−/− mice

Although uterine GR1+ cells did not produce TNF-α (Fig. 7A) and their depletion did not lead to pregnancy rescue, it is still not clear whether these cells were activated and harbor a cytotoxic phenotype. In this regard, we examined production of reactive oxygen species (ROS) by GR1+ uterine cells as it is a specific phenotype of these cells upon activation (43, 44). To assess the production of ROS, we utilized dihydrorhodamine (DHR) in flow cytometric analysis. This molecule increases its fluorescent intensity upon oxygenation, and has recently been employed to measure production of ROS in several studies (45). CD45+/CD11b+/GR1+ cells were typed from gd9 or gd15 uteroplacental tissue from control ODN or CpG ODN-treated IL-10−/− mice and stained simultaneously with DHR as described in Materials and Methods. Uterine CD45+/CD11b+/GR1+cellular populations from CpG ODN-treated tissue harvested on gd9 (Fig. 7B) or gd15 (data not shown) show a significant increase in DHR fluorescence, as calculated by an increase in MFI (mean fluorescent intensity), compared to that seen in tissues from control ODN-treated mice. These data clearly suggest that uterine GR1+ cells acquire an activated phenotype in CpG ODN-treated IL-10−/− mice as depicted by ROS production. However, as GR1+ depletion did not rescue negative pregnancy outcomes in response to CpG ODN, ROS production by GR1+ cells may cause placental cell death in conjunction with cytokines that may be produced by other activated uterine immune cells.

F4/80+ cellular depletion abrogates TNF-α production in IL-10−/− mice leads to term pregnancy

We next examined the uterine cell type associated with TNF-α production in order to define the mechanism of fetal demise at a cellular level. Because GR1+ cellular depletion proved inadequate as a means to rescue pregnancy, we examined the potential contribution of macrophages in CpG ODN-induced adverse pregnancy outcomes. In the fetal resorption setting, we injected an anti-F4/80 antibody i.p. on gd5 and gd7 with CpG ODN injection on gd6. For the preterm birth condition, the anti-F4/80 antibody was injected on gd13 prior to gd14 injection of CpG ODN. As shown in Fig. 8A, F4/80 antibody treatment rescued pregnancy as the feto-placental units harvested on gd10 remained intact, and mice that were allowed to proceed to term delivered healthy litters (Table I). Similarly as is shown in Table I, preterm birth effects in response to CpG ODN were abrogated in response to anti-F4/80 antibody injection. In order to ensure that F4/80+ cells were depleted, we analyzed CD45+ uterine mononuclear and granular cell population by FACS for the presence of an F4/80+ population. As shown in Fig. 8B, uterine F4/80+ cells were successfully depleted below those of control levels. CpG ODN, however, amplified the proportional presence of F4/80+ cells upwards of 20% similar to results shown in Fig. 3 and Fig. 5. Importantly, we assessed intracellular TNF-α production from CpG ODN-treated mice depleted or not depleted for F4/80+ cells from gd9 uteroplacental tissues. In the F4/80+ depleted mice, there was a lack of intracellular staining for TNF-α as compared to levels seen in response to CpG ODN alone (Fig. 8B). These data suggest a causative role of uterine macrophages in inducing adverse pregnancy outcomes in CpG ODN-treated IL-10−/− mice.

Figure 8
Macrophage depletion abrogates CpG ODN-mediated negative fetal outcomes, and diminishes TNF-[alpha]activity

Discussion

It is widely accepted that the innate immune system is essential as a dynamic factor that could be both protective and detrimental to the maternal-fetal stasis (3, 810). Although its role is poorly understood, the relative presence of the TLR system in the placental microenvironment further adds to this complexity. Growing evidence clearly suggests that TLR-mediated activation through endogenous signals may indeed provide pregnancy compatible responses (12, 46). On the other hand, it is not yet fully understood how the TLR machinery will respond to external signals with origins from intrauterine infections and inflammation, particularly when coupled with intrinsic deficiencies in molecules that are critical to normal pregnancy outcome. Two such scenarios are the bacterial and viral DNA breakdown products represented by unmethylated CpG ODN motifs and double-stranded RNA.

In this study, we have examined the gestational age-dependent consequences of CpG ODN administration in pregnant wild type and IL-10−/− mice. We observed that when injected i.p. on gd6 or gd14, CpG ODN caused rapid fetal resorption or preterm stillbirth in IL-10−/− mice, respectively (Fig. 1). In contrast, a similar low dose or a 10 fold higher CpG ODN dose failed to exert any adverse pregnancy effects in WT mice. CpG ODN-mediated consequences in IL-10−/− mice were TLR-9 specific as an antagonistic CpG ODN ligand rescued pregnancy in response to pathogenic CpG ODN (Fig. 2B). These observations point to a protective role of IL-10 at the maternal-fetal interface when challenged with bacterial or viral pathogens that may give rise to CpG-like breakdown products.

Several key features were noted in pregnant IL-10−/− mice when challenged with the pathogenic CpG ODN motif. First, the induction of fetal resorption or preterm birth was rapid and severe (Fig. 2A). In comparison, WT mice only experienced teratogenic effects at a very high dose (~400 µg/dam) in a portion of the litter at term. Second, the functional presence of uterine CD11b+/F4/80+ macrophages and CD11b+/GR1+ neutrophils (Fig. 3), not CD11c+ dendritic cells or NK1.1+/CD3 NK cells, was significantly increased. This influx was critically associated with a drastic increase in serum and the local presence of mKC (Fig. 4). Uterine macrophages, not GR1+ neutrophils, exhibited significantly high production of TNF-α (Fig. 8). Importantly, both cell types uncharacteristically migrated to the placental zone (Fig. 5). Finally, depletion of F4/80+ cells (Fig. 8) or in vivo neutralization of TNF-α (Fig. 6E) in CpG-treated IL-10−/− mice blunted fetal resorption and preterm birth and rescued pregnancy to term (Table I).

It is important to mention that depletion of GR1+ cells did not lead to rescue of pregnancy nor did it reduce the presence of TNF-α -producing uterine cells (Fig. 7). Thus, when encountered in an abortion- or preterm birth-prone environment such as IL-10 deficiency, TLR-9-triggered cytotoxic activation of macrophages and TNF-α production has severe pathologic effects on pregnancy. Neutrophils may influence pregnancy outcome mainly through production of reactive oxygen species (Fig. 7). These results are important in light of the numerous reports on the association of bacterial and viral infections with early and late pregnancy loss in humans (1, 2, 47, 48). In connection with these data, recent cohort studies have demonstrated that women with abnormally low IL-10 production are more susceptible to systemic and intrauterine infections, leading to increased incidence of pregnancy loss (4952).

TLR-9, localized in intracellular compartments, is expressed in both innate and adaptive immune cells and has been shown to be present in uterine immune cells (11, 14, 15). Curiously, human placental explants did not show any response to CpG compared to agonists for other TLRs (12), suggesting that in humans the maternal immune cells are the major target for CpG-mediated effects. It is possible that TLR-9 remains localized to the endoplasmic reticulum of the trophoblast in a non-functional form, whereas it becomes activated by localizing to and undergoing cleavage in endolysosomes in uterine macrophages and neutrophils (53, 54). TLR-9 signaling has been shown to be essential for recruitment and activation of NK and dendritic cells in many settings of parasitic and bacterial infections (55). TLR-9−/− mice have been shown to lack cytotoxic activation of these cells following infection with Leishmania (L.) major (56). Since we did not observe cytotoxic activation of uNK cells, it is possible that these cells behave differently in response to pathogenic TLR-9 agonists than circulating NK cells.

Our findings of high levels of mKC are critical for implications toward understanding the balance between maternal and fetal health. IL-8 has been shown to be imperative for proper trophoblast cell invasion in humans (6). On the other hand, dysregulated production of this chemokine in response to a TLR-9-mediated inflammatory insult could prove to be highly detrimental by way of the robust recruitment of cytotoxic macrophages and neutrophils.

We have shown an increased incidence of two cellular populations in response to CpG-mediated pathogens in IL-10−/− mice, namely macrophages and neutrophils (Fig. 3 and Fig. 5). While the response of these cells to this TLR-9 ligand is widely expected (57, 58), this is the first time it has been documented in the context of pregnancy and the uterine microenvironment. We have elucidated novel mechanisms involving these two cell types as first responders to CpG-mediated inflammatory insult, and we have parsed apart their individual roles in this system. Importantly, we have linked the role of macrophages with the production of TNF-α in response to CpG challenge during pregnancy (Fig. 8). Based on our recent findings with other TLR ligands (9, 10, unpublished observations), we propose that TNF-α is a common final product in response to a spectrum of TLR agonists that induce adverse pregnancy outcomes in response to systemic administration. As shown in Fig. 6 and Table I, neutralization of TNF-α resulted in rescue of pregnancy to term suggesting that renewed focus should be assigned to the cellular producers of this cytotoxin in response to a particular TLR that is activated. An understanding of the cellular diversity of TNF-α production at the maternal-fetal interface may be essential in providing proper therapeutic interventions in the context of pregnancy complications.

Acknowledgments

We thank Dr. Alfred Ayala and the Sharma laboratory for critical reading and helpful comments. We also thank Paula Weston for assistance with immunohistochemical analysis.

Abbreviations used in this paper

uNK
uterine Natural Killer
TLRs
Toll-like receptors
ODN
oligodeoxynucleotide
UMGC
uterine mononuclear and granular cells
DHR
dihydrorhodamine

Footnotes

Disclosures

The authors have no financial conflict of interest.

1This work was supported in part by a grant from NIH NCRR (P20RR018728), the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH and a subcontract WSU05056 under NICHD Contract #N01-HD-2-3342. Jessica E. Thaxton was supported by a Superfund Basic Research Program Award (P42ES013660) from the NIEHS.

References

1. Goldenberg RL, Hauth JC, Andrew WW. Intrauterine infection and preterm delivery. N. Engl. J. Med. 2000;342:1500–1507. [PubMed]
2. Romero R, Espinoza J, Mazor M. Can endometrial infection/inflammation explain implantation failure, spontaneous abortion, and preterm birth after in vitro fertilization? Fertil. Steril. 2004;82:799–804. [PubMed]
3. Moffett-King A. Natural Killer Cells and Pregnancy. Nat. Rev. Immunol. 2002;2:656–663. [PubMed]
4. Whitelaw PF, Croy BA. Granulated lymphocytes of pregnancy. Placenta. 1996;17:533–543. [PubMed]
5. Ain R, Canham LN, Soares MJ. Gestational stage-dependent intrauterine trophoblast cell invasion in the rat and mouse: novel endocrine phenotype regulation. Dev. Biol. 2003;260:176–190. [PubMed]
6. Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, Prus D, Cohen-Daniel L, Arnon TI, Manaster I, Gazit R, Yutkin V, Benharroch D, Porgador A, Keshet E, Yagel S, Mandelboim O. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat. Med. 2006;12:1065–1074. [PubMed]
7. Kalkunte S, Chichester CO, Gotsch F, Sentman CL, Romero R, Sharma S. Evolution of non-cytotoxic uterine natural killer cells. Am. J. Reprod. Immunol. 2008;59:425–432. [PMC free article] [PubMed]
8. Kalkunte S, Mselle TF, Norris WE, Wira CR, Sentman CL, Sharma S. VEGF C facilitates immune tolerance and endovascular activity of human uterine NK cells at the maternal-fetal interface. J. Immunol. 2009 In press. [PMC free article] [PubMed]
9. Murphy SP, Fast LD, Hanna NN, Sharma S. Uterine NK cells mediate inflammation-induced fetal demise in IL-10-null mice. J. Immunol. 2005;175:4084–4090. [PubMed]
10. Murphy SP, Hanna NN, Fast LD, Shaw SK, Berg G, Padbury JF, Romero R, Sharma S. Evidence for participation of uterine NK cells in the mechanisms responsible for spontaneous preterm labor and delivery. Am. J. Obstet. Gynecol. 2009;200:308e1–308e9. [PubMed]
11. Sentman CL, Wira CR, Eriksson M. NK cell function in the human female reproductive tract. Am. J. Reprod. Immunol. 2007;57:108–115. [PubMed]
12. Patni S, Wynen LP, Seager AL, Morgan G, White JO, Thornton CA. Expression and Activity of Toll-Like Receptors 1–9 in the human term placenta and changes associated with labor at term. Biol Reprod. 2009;80:243–248. [PubMed]
13. Krikun G, Lockwood CJ, Abrahams VM, Mor G, Paidas M, Guller S. Expression of Toll-like receptors in the human decidua. Histol. Histopathol. 2007;22:847–854. [PubMed]
14. Barton GM, Medzhitov R. Toll-like receptors and their ligands. Curr. Top. Microbiol. Immunol. 2002;270:81–92. [PubMed]
15. Uematsu S, Akira S. Toll-like receptors and innate immunity. J. Mol. Med. 2006;84:712–725. [PubMed]
16. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 2007;7:179–190. [PubMed]
17. Krieg AM. CpG Motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002;20:709–760. [PubMed]
18. Pedersen G, Andresen L, Matthiessen MW, Rask-Madsen J, Brynskov J. Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium. Clin. Exp. Immunol. 2005;141:298–306. [PubMed]
19. Prater MR, Johnson VJ, Germolec DR, Luster MI, Holladay SD. Maternal treatment with a high dose of CpG ODN during gestation alters fetal craniofacial and distal limb development in C57BL/6 mice. Vaccine. 2006;24:263–271. [PubMed]
20. Ito S, Ishii KJ, Shirota H, Klinman DM. CpG oligodeoxynucleotides improve survival of pregnant and fetal mice following Listeria Monocytogenes infection. Infect. Immun. 2004;72:354–358. [PMC free article] [PubMed]
21. Carpentier AF, Chen L, Maltonti F, Delattre JY. Oligodeoxynucleotides containing CpG motifs can induce rejection of neuroblastoma in mice. Cancer Res. 1999;59:5429–5432. [PubMed]
22. Carpentier AF, Xie J, Mokhtari K, Delattre JY. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin. Cancer Res. 2000;6:2469–2473. [PubMed]
23. Meng Y, Carpentier AF, Chen L, Boisserie G, Simon JM, Mazeron JJ, Delattre JY. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int. J. Cancer. 2005;116:992–997. [PubMed]
24. Becker Y. CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations – a review, hypothesis and implications. Virus Genes. 2005;30:251–266. [PubMed]
25. Kline JN, Krieg AM. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect. 2008;21:434–439. [PubMed]
26. Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsch V, Al-Adhami M, Readett D, Krieg AM, Leichman CG. Randomized phase II trial of toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced stage non-small-cell lung cancer. J. Clin. Oncol. 2008;26:3979–3986. [PubMed]
27. Chaung HC. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy. Int. Immunopharmacol. 2006;6:1586–1596. [PubMed]
28. Jenkins M, Parker C, Tuo W, Vinyard B, Dubey JP. Inclusion of CpG adjuvant with plasmid DNA coding for NcGRA7 improves protection against congenital neosporosis. Infect. Immun. 2004;72:1817–1819. [PMC free article] [PubMed]
29. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ. Divergent therapeutic and immunologic effect of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 2001;167:4878–4886. [PubMed]
30. Beloeil L, Tomkowiak M, Angelov G, Walzer T, Dubois P, Marvel J. In vivo impact of CpG1826 oligodeoxynucleotide on CD8 T cell primary responses and survival. J. Immunol. 2003;171:2295–3002. [PubMed]
31. Dragoi AM, Fu X, Ivanov S, Zhang P, Sheng L, Wu D, Li GC, Chu WM. DNA-PKcs, but not TLR9, is required for activation of Akt by CpG-DNA. EMBO J. 2005;24:779–789. [PubMed]
32. Verthelyi D, Zeuner AR. Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends Immunol. 2003;24:519–522. [PubMed]
33. Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, Yi AK, Short D, Davis HL. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. 1998;95:12631–12636. [PubMed]
34. Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F, Klinman DM. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J. Immunol. 2003;171:1393–1400. [PubMed]
35. Stunz LL, Lenert P, Peckham D, Yi AK, Haxhinasto S, Chang M, Krieg AM, Ashman RF. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur. J. Immunol. 2002;32(5):1212–1222. [PubMed]
36. Piccini MP. T cells in pregnancy. Chem. Immunol. Allergy. 2005;89:3–9. [PubMed]
37. Renaud SJ, Graham CH. The role of macrophages in utero-placental interactions during normal and pathological pregnancy. Immunol. Invest. 2008;37:535–564. [PubMed]
38. Rothenfusser S, Tuma E, Endres S, Hartmann G. Plasmacytoid dendritic cells: the key to CpG. Hum. Immunol. 2002;63:1111–1119. [PubMed]
39. Nardini E, Morelli D, Aiello P, Besusso D, Calcaterra C, Mariani L, Palazzo M, Vecchi A, Paltrinieri S, Menard S, Balsari A. CpG-oligodeoxynucleotides induce mobilization of hematopoetic progenitor cells into peripheral blood in association with mouse KC (IL-8) production. J. Cell Physiol. 2005;204:889–895. [PubMed]
40. Wood GW, Hausmann E, Choudhuri R. Relative role of CSF-1, MCP-1/JE, and RANTES in macrophage recruitment during successful pregnancy. Mol. Reprod. Dev. 1997;46:62–69. [PubMed]
41. Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J. Leukoc. Biol. 2008;83:64–70. [PubMed]
42. Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides. Int. Rev. Immunol. 2006;25:135–154. [PubMed]
43. Lee JG, Lee SH, Park DW, Lee SH, Yoon HS, Chin BR, Kim JH, Kim JR, Baek SH. Toll-like receptor 9-stimulated monocyte chemoattractant protein-1 is mediated via JNK-cytosolic phospholipase A2-ROS signaling. Cell Signal. 2008;20:105–115. [PubMed]
44. József L, Khreiss T, El Kebir D, Filep JG. Activation of TLR-9 induces IL-8 secretion through peroxynitrite signaling in human neutrophils. J. Immunol. 2006;176:1195–1202. [PubMed]
45. Redecha P, Tilley R, Tencati M, Salmon JE, Kirchhofer D, Mackman N, Girardi G. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood. 2007;110:2423–2431. [PubMed]
46. Mor G, Romero R, Aldo PB, Abrahams VM. Is the trophoblast an immune regulator? The role of Toll-like receptors during pregnancy. Crit. Rev. Immunol. 2005;25:375–388. [PubMed]
47. Mosca F, Pugni L. Cytomegalovirus infection: the state of the art. J. Chemother. 2007;2:46–48. [PubMed]
48. Pararas MV, Skevaki CL, Kafetzis DA. Preterm birth due to maternal infection: Causative pathogens and modes of prevention. Eur. J. Clin. Microbiol. Infect. Dis. 2006;25:562–569. [PubMed]
49. Hanna N, Bonifacio L, Weinberger B, Reddy P, Murphy S, Romero R, Sharma S. Evidence for interleukin-10-mediated inhibition of cyclo-oxygenase-2 expression and prostaglandin production in preterm human placenta. Am. J. Reprod. Immunol. 2006;55:19–27. [PubMed]
50. Annells MF, Hart PH, Mullighan CG, Heatley SL, Robinson JS, Bardy P, McDonald HM. Interleukins-1, -4, -6, -10, tumor necrosis factor, transforming growth factor-beta, FAS, and mannose-binding protein C gene polymorphisms in Australian women: Risk of preterm birth. 2004. Am. J. Obstet. Gynecol. 2004;191:2056–2067. [PubMed]
51. Kerk J, Bartels DB, Brinkhaus MJ, Dammann CE, Dörk T, Mammann. O. Multiplex measurement of cytokine/receptor gene polymorphisms and interaction between interleukin-10 (-1082) genotype and chorioamnionitis in extreme preterm delivery. J. Soc. Gynecol. Investig. 2006;13:350–356. [PubMed]
52. Menon R, Merialdi M, Lombardi SJ, Fortunato SJ. Differences in the placental membrane cytokine response: a possible explanation for the racial disparity in preterm birth. Am. J. Reprod. Immunol. 2006;56:112–118. [PubMed]
53. Kim YM, Brinkmann MM, Paquet ME, Ploegh HL. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature. 2008;452:234–238. [PubMed]
54. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 2004;5:190–198. [PubMed]
55. Bhan U, Lukacs NW, Osterholzer JJ, Newstead MW, Zeng X, Moore TA, McMillan TR, Krieg AM, Akira S, Standiford TJ. TLR9 is required for protective innate immunity in Gram-negative bacterial pneumonia: role of dendritic cells. J. Immunol. 2007;179:3937–3946. [PubMed]
56. Liese J, Schleicher U, Bogdan C. TLR9 signaling is essential for the innate NK cell response in murine cutaneous leishmaniasis. Eur. J. Immunol. 2007;37:3424–3434. [PubMed]
57. Buhtoiarov IN, Sondel PM, Eickhoff JC, Rakhmilevich AL. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides. Immunology. 2007;120:412–423. [PubMed]
58. Alvarez ME, Fuxman Bass JI, Geffner JR, Calotti PX, Costas M, Coso OA, Gamberale R, Vermeulen ME, Salamone G, Martinez D, Tanos T, Trevani AS. Neutrophil signaling pathways activated by bacterial DNA stimulation. J. Immunol. 2006;177:4037–4046. [PubMed]
59. Roche JK, Keepers TR, Gross LK, Seaner RM, Obrig TG. CXCL1/KC and CXCL2/MIP-2 are critical effectors and potential targets for therapy of Escherichia coli 0157:H7-Associated Renal Inflammation. Am. J. Pathol. 2007;170:526–537. [PubMed]
60. Siewe L, Bollati-Fogolin M, Wickenhauser C, Krieg T, Muller W, Rogers A. Interleukin-10 derived from macrophages and/or neutrophils regulates the inflammatory response to LPS but not the response to CpG DNA. Eur. J. Immunol. 2006;36:3248–3255. [PubMed]